BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 272 filers reported holding BLUEBIRD BIO INC in Q4 2020. The put-call ratio across all filers is 1.17 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $334,400 | -7.6% | 110,000 | 0.0% | 0.00% | -42.9% |
Q2 2023 | $361,900 | -93.9% | 110,000 | -40.7% | 0.01% | -91.0% |
Q2 2021 | $5,931,000 | -48.4% | 185,418 | -51.4% | 0.08% | -68.5% |
Q1 2021 | $11,489,000 | +1560.3% | 381,157 | +2282.2% | 0.25% | +1450.0% |
Q4 2020 | $692,000 | -57.3% | 16,000 | -46.7% | 0.02% | -57.9% |
Q3 2020 | $1,620,000 | -53.0% | 30,000 | -46.9% | 0.04% | -67.0% |
Q2 2020 | $3,448,000 | +32.6% | 56,500 | -0.2% | 0.12% | -21.8% |
Q1 2020 | $2,601,000 | -61.5% | 56,600 | -26.5% | 0.15% | -35.2% |
Q4 2019 | $6,757,000 | +32.8% | 77,000 | +39.0% | 0.23% | -14.3% |
Q3 2019 | $5,087,000 | +116.2% | 55,400 | +199.5% | 0.26% | +124.6% |
Q2 2019 | $2,353,000 | -70.1% | 18,500 | -63.0% | 0.12% | -72.8% |
Q1 2019 | $7,866,000 | +2166.9% | 50,000 | +1328.6% | 0.43% | +1450.0% |
Q4 2018 | $347,000 | -63.5% | 3,500 | -46.2% | 0.03% | -46.2% |
Q3 2018 | $950,000 | +34.6% | 6,500 | +44.4% | 0.05% | -5.5% |
Q2 2018 | $706,000 | – | 4,500 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 4,282,827 | $13,019,794 | 1.84% |
Birchview Capital, LP | 455,200 | $1,383,808 | 1.18% |
PFM Health Sciences, LP | 6,040,934 | $18,364,439 | 0.86% |
Lion Point Capital, LP | 531,256 | $1,615,018 | 0.72% |
Endurant Capital Management LP | 251,785 | $765,426 | 0.69% |
Bleichroeder LP | 900,000 | $2,736,000 | 0.67% |
Connacht Asset Management LP | 31,634 | $96,167 | 0.57% |
Granahan Investment Management | 5,137,778 | $15,618,845 | 0.56% |
Frazier Life Sciences Management, L.P. | 1,709,907 | $5,198,117 | 0.34% |
Contrarius Investment Management Ltd | 1,308,002 | $3,976 | 0.22% |